Influx Healthtech Limited gets in-principal listing approval from NSE

Mumbai-based healthcare focused company Influx Healthtech Limited has received in-principal approval from exchange to list on the bourse.

The company had filed its draft papers with NSE Emerge on February 4, 2025. 

The IPO, with a face value of Rs 10 per equity share, is a mix of fresh issue of up to 50,00,400 equity shares with an offer of sale up to 11,00,400 equity shares by Munir Abdul Ganee Chandniwala. The offer also includes a reservation for a subscription by market makers in the market maker reservation portion.

The proceeds from its fresh issuance will be utilized to the extent of Rs 13.23 crore for purchase of Machinery for setting up of new manufacturing facility for Nutraceutical Division; Rs 4.10 crore for purchase of Machinery for setting up of new manufacturing facility for Veterinary Food Division; Rs 2.75 crore for Purchase of Machineries for Homecare and Cosmetic Division.

Mumbai-based Influx Healthtech Limited was established in 2020 by Mr. Munir Abdul Ganee Chandniwala, the company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.

The company operates manufacturing facilities located in Thane, Maharashtra, and has an expertise that spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.

Influx Healthtech’s revenue from operations increased by 31.44% from ₹ 76.05 crore in the financial year ended March 31, 2023 to ₹ 99.97 crore in the financial year ended March 31, 2024. Profit after tax increased from ₹ 7.20 crore in the financial year ended March 31, 2023 to ₹ 11.22 crore in the financial year ended March 31, 2024.

For the seven months ended November 30, 2024, revenue from operations stood at Rs 62.75 crore, and profit after tax stood at Rs 8.04 crore.

Rarever Financial Advisors Private Limited is the sole lead manager, and Maashitla Securities Private Limited is the registrar of the issue.